The first participants have been vaccinated with an investigational Ebola Sudan vaccine candidate provided by IAVI, a nonprofit scientific ...

In addition, genetically modified plants may someday be used to produce recombinant vaccines. In fact ... such as avoiding superfluous DNA transfer (vector sequences) and replacing selectable ...

The main types include recombinant subunit vaccines, nucleic acid vaccines, recombinant live vector vaccines, gene deletion/mutation vaccines and plant vaccines. Aquatic vaccines have been widely used ...

Just 12 months prior to the Coronavirus disease 2019 (COVID-19) pandemic our team received funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to establish and validate a rapid ...

NEW YORK CITY, NY / ACCESS Newswire / February 3, 2025 / The first participants have been vaccinated with an investigational Ebola Sudan vaccine candidate provided by IAVI, a nonprofit scientific ...

While Robert F. Kennedy Jr., President Donald Trump’s pick to lead the US Department of Health and Human Services, has backpedaled on his anti-vaccine rhetoric during his Senate confirmation ...

Inactivated virus, viral vector, bacterial vector, subunit and DNA vaccines encoding several antigens have been developed and shown to be immunogenic. Vaccine trials in animal models that mimic ...

A variety of vaccine approaches, however, have been investigated using both inactivated virus and recombinant DNA technology. These approaches will be further discussed later in this review.

Recombinant antibodies help study immune responses and evaluate vaccine efficacy. In this way, they contribute to the rapid development of vaccines against complex infectious diseases like COVID-19.

17 The three types of influenza vaccines currently approved for use include Inactivated (IIV), Live-Attenuated (LAIV) and Recombinant (RIV) influenza vaccines (Table 1). 25 All three vaccine platforms ...

This approach uses co-infection with a transgene-containing vector and a second vector encoding multiple enhancer sequences. Using this cis-activation strategy in primary cells and muscle ...

Other vaccine types (eg, mRNA, viral vector or protein subunit type) need to be studied for validation, ideally prospectively and with multicentre collaboration. In conclusion, this study suggests ...